Neos Therapeutics, Inc.
(NASDAQ : NEOS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.58%183.626.2%$89.29m
AMRNAmarin Corporation Plc Sponsored ADR
2.03%17.631.8%$87.15m
SAGESAGE Therapeutics, Inc.
0.07%175.398.7%$78.03m
PRGOPerrigo Co. Plc
-0.92%47.336.8%$66.85m
ICPTIntercept Pharmaceuticals, Inc.
2.71%87.8318.6%$65.78m
UTHRUnited Therapeutics Corporation
1.76%87.5014.3%$60.69m
JAZZJazz Pharmaceuticals Plc
-0.48%136.762.3%$59.46m
ZYNEZynerba Pharmaceuticals Inc
-2.59%13.188.3%$40.24m
ICLRICON Plc
1.72%140.904.1%$40.17m
MDCOMedicines Company
1.99%34.8821.8%$40.01m
MNKMallinckrodt Plc
5.71%9.6221.0%$38.56m
CTLTCatalent Inc
0.04%46.212.4%$35.83m
AXSMAxsome Therapeutics, Inc.
4.92%24.732.1%$35.40m
HZNPHorizon Pharma plc
0.94%24.836.7%$35.35m
PCRXPacira Pharmaceuticals, Inc.
0.00%43.3310.5%$33.46m

Company Profile

Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.